Swedish biotech venture LIDDS AB has received approval from the Danish Medicines Agency (DKMA) to conduct a Phase I trial–NZ-DTX-001. This is in addition to a study already approved in Sweden at the Karolinska University Hospital. The aim of the trial is to assess the tolerability and safety of intratumoral injections of NanoZolid® with doceaxel, a well-established cytostatic used in the treatment of cancer with an estimated global market of over $1 billion. LIDDS expects to enroll its first patients in the NZ-DTX-001 trial in Q1 2019. Their goal is to deliver drugs directly into the cancer tumor and thereby limit the severe side effects for cancer sufferers receiving systemic chemotherapy treatments which affect all cells in the body. The NZ-DTX-001 study is a phase 1a/1b first-in-human, open label, multicenter, dose-escalation and dose-expansion study of a novel NanoZolid-docetaxel depot formulation (NZ-DTX Depot) given as an intratumoral injection in patients with advanced solid tumors.
Monica Wallter, CEO LIDDS Pharma